Insider Selling: Schrodinger (NASDAQ:SDGR) Insider Sells $928,062.63 in Stock

Schrodinger, Inc. (NASDAQ:SDGRGet Free Report) insider Karen Akinsanya sold 31,599 shares of Schrodinger stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $29.37, for a total transaction of $928,062.63. Following the completion of the transaction, the insider directly owned 69,956 shares of the company’s stock, valued at approximately $2,054,607.72. This represents a 31.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Schrodinger Stock Performance

Shares of NASDAQ:SDGR opened at $29.23 on Thursday. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of -39.50 and a beta of 1.69. Schrodinger, Inc. has a 1-year low of $10.94 and a 1-year high of $31.59. The company’s fifty day moving average is $19.34 and its two-hundred day moving average is $15.57.

Schrodinger (NASDAQ:SDGRGet Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.41) by $0.49. The business had revenue of $58.89 million during the quarter, compared to analyst estimates of $47.19 million. Schrodinger had a negative net margin of 20.98% and a negative return on equity of 16.37%. The company’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.65) EPS. Sell-side analysts expect that Schrodinger, Inc. will post -1.5 EPS for the current fiscal year.

Institutional Trading of Schrodinger

Hedge funds and other institutional investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC acquired a new stake in shares of Schrodinger in the second quarter valued at $102,000. Squarepoint Ops LLC grew its holdings in Schrodinger by 290.4% during the second quarter. Squarepoint Ops LLC now owns 209,123 shares of the company’s stock worth $3,398,000 after acquiring an additional 155,556 shares during the period. Allworth Financial LP raised its position in Schrodinger by 252.3% in the second quarter. Allworth Financial LP now owns 5,270 shares of the company’s stock worth $86,000 after acquiring an additional 3,774 shares in the last quarter. Corient Private Wealth LP bought a new stake in Schrodinger in the second quarter worth about $303,000. Finally, Beacon Pointe Advisors LLC acquired a new stake in Schrodinger in the 2nd quarter valued at about $839,000. Institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. UBS Group assumed coverage on Schrodinger in a report on Friday, August 14th. They issued a “neutral” rating and a $19.00 price target on the stock. Weiss Ratings upgraded Schrodinger from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Finally, Wall Street Zen raised shares of Schrodinger from a “strong sell” rating to a “hold” rating in a report on Saturday, August 8th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $20.50.

Read Our Latest Research Report on SDGR

About Schrodinger

(Get Free Report)

Schrödinger, Inc develops computational software designed to accelerate drug discovery and materials science research. Its platform uses physics-based modeling, machine learning and related computational methods to help scientists analyze molecular structures, predict interactions and identify potential compounds for further development.

The company’s software products support a range of research activities, including molecular modeling, virtual screening, structure-based drug design, free-energy calculations and collaborative data management.

Recommended Stories

Insider Buying and Selling by Quarter for Schrodinger (NASDAQ:SDGR)

Receive News & Ratings for Schrodinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrodinger and related companies with MarketBeat.com's FREE daily email newsletter.